Numerous studies have validated this relationship [22,23], and new findings have been made, such as its relationship to ALT [24] serum levels and the full spectrum of NAFLD, including simple steatosis, steatohepatitis, cirrhosis and hepatocellular carcinoma [25,26], as well as systemic disorders more frequent in these patients, such as cardiovascular risk. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.